Lekovi protiv gojaznosti (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lekovi protiv gojaznosti" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

4web.archive.org

1^st place

3nih.gov

4^th place

3^rd place

2fda.gov

447^th place

642^nd place

1nice.org.uk

3,258^th place

1,943^rd place

1cbc.ca

115^th place

323^rd place

1europa.eu

68^th place

64^th place

1hc-sc.gc.ca

low place

4,131^st place

1annals.org

low place

789^th place

1nature.com

234^th place

154^th place

1doi.org

2^nd place

annals.org

Snow V, Barry P, Fitterman N, Qaseem A, Weiss K (2005). „Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians”. Ann. Intern. Med. 142 (7): 525–31. PMID 15809464.

cbc.ca

„Anti-obesity drug no magic bullet”. Canadian Broadcasting Corporation. 2. 1. 2007.. Arhivirano iz originala na datum 2007-01-05. Pristupljeno 19. 9. 2008.

doi.org

dx.doi.org

Cooke D, Bloom S (2006). „The obesity pipeline: current strategies in the development of anti-obesity drugs”. Nature reviews. Drug discovery 5 (11): 919–31. DOI:10.1038/nrd2136. PMID 17080028.

europa.eu

emea.europa.eu

„www.emea.europa.eu”. Arhivirano iz originala na datum 2008-11-06. Pristupljeno 2014-03-25.

fda.gov

„www.fda.gov”.
„FDA Briefing Document NDA 21-888 Zimulti (rimonabant) Tablets, 20 mg Sanofi Aventis Advisory Committee” (PDF). Food and Drug Administration. 13. 6. 2007.. Arhivirano iz originala na datum 2008-09-10. Pristupljeno 19. 9. 2008.

hc-sc.gc.ca

„Abbott Laboratories Voluntarily Withdraws Weight-loss Drug Sibutramine (Meridia) from the Canadian Market – Health Canada Information Update 2010-10-08”.

nature.com

Cooke D, Bloom S (2006). „The obesity pipeline: current strategies in the development of anti-obesity drugs”. Nature reviews. Drug discovery 5 (11): 919–31. DOI:10.1038/nrd2136. PMID 17080028.

nice.org.uk

guidance.nice.org.uk

National Institute for Health and Clinical Excellence. Clinical guideline 43: Obesity: The prevention, identification, assessment and management of overweight and obesity in adults and children. London, 2006.

nih.gov

ncbi.nlm.nih.gov

Snow V, Barry P, Fitterman N, Qaseem A, Weiss K (2005). „Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians”. Ann. Intern. Med. 142 (7): 525–31. PMID 15809464.
Cooke D, Bloom S (2006). „The obesity pipeline: current strategies in the development of anti-obesity drugs”. Nature reviews. Drug discovery 5 (11): 919–31. DOI:10.1038/nrd2136. PMID 17080028.

win.niddk.nih.gov

„WIN – Publication – Prescription Medications for the Treatment of Obesity”. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Institutes of Health. Arhivirano iz originala na datum 2009-01-13. Pristupljeno 14. 1. 2009.

web.archive.org

„WIN – Publication – Prescription Medications for the Treatment of Obesity”. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Institutes of Health. Arhivirano iz originala na datum 2009-01-13. Pristupljeno 14. 1. 2009.
„Anti-obesity drug no magic bullet”. Canadian Broadcasting Corporation. 2. 1. 2007.. Arhivirano iz originala na datum 2007-01-05. Pristupljeno 19. 9. 2008.
„FDA Briefing Document NDA 21-888 Zimulti (rimonabant) Tablets, 20 mg Sanofi Aventis Advisory Committee” (PDF). Food and Drug Administration. 13. 6. 2007.. Arhivirano iz originala na datum 2008-09-10. Pristupljeno 19. 9. 2008.
„www.emea.europa.eu”. Arhivirano iz originala na datum 2008-11-06. Pristupljeno 2014-03-25.